Creating Inclusive KAP Training Practices with TRIPP Founder Jennifer Montjoy
Discussing the lack of diversity in the psychedelics space with Jennifer Montjoy.
Similar Posts
Kevin O’Leary Thinks MindMed, Compass Pathways & atai Will Merge | Is this a Good Idea?
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
Back to the potential MindMed, Compass Pathways & atai merger that Kevin O
Leary speculates on…
Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?
The “Shark Tank” star predicts three of the biggest psychedelic companies will merge into a mega-corporation, but our resident Psychedelic Investor wonders: Should they?
Famed investor Kevin O’Leary made a bold prediction last Tuesday, saying that psychedelic companies MindMed, atai Life Sciences and Compass Pathways will merge. For psychedelic stock investors, this would be a tsunami-sized event that would have ripple effects throughout the industry.
The Shark Tank star made the comments at the inaugural Benzinga Psychedelics Capital Conference in Miami, arguing that the companies “each need another $200 million by the time they get this to medicine.” In other words, as I have written before, the psychedelic medicines industry is heavily capital intensive, and getting multiple drugs from pre-clinical trials through Phase 3 trials and approved by the FDA can cost hundreds of millions of dollars.
Even though these companies are three of the best-financed in the industry — atai (Nasdaq: atai) has $362 million, Compass (Nasdaq: CMPS) has $273 million and MindMed (Nasdaq: MNMD, NEO: MMED) has $133 million — the celebrity investor believes that in order to succeed the companies may have to become one.
Read the entire article here: https://psychedelicspotlight.com/kevin-oleary-predicts-3-biggest-psychedelic-companies-will-merge-atai-mindmed-compass-pathways/
One man claims magic mushrooms healed his lost sense of smell. Read the full story here.
https://whyy.org/segments/could-magic-mushrooms-cure-covid-related-smell-loss/
A new anti-depressant study is out. Read the full study here: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0265928#sec011
#Mindmed #kevinoleary #psychedelicstocks
Philadelic Conference Brings Together Interdisciplinary Experts to Advance Understanding of Psychedelics
The Philadelic Conference cultivates a setting of diverse experts to facilitate meaningful discussion, foster ideas, and expand understanding.
The History of LSD: A Story of Self-Experimentation
Despite the LSD experience lasting only two hours, Hofmann was amazed at the power of his creation. And like any good scientist, he knew exactly what he had to do: self-experiment.
Psychedelic Users Experienced Less Psychological Stress During COVID-19 Lockdowns, Study Finds
Researchers found stress further reduced for the participants that use psychedelic drugs at least once every six months.
Hawaii Moves One Step Closer To Creating A Therapeutic Psilocybin Working Group
The Aloha State’s Senate Committee recently approved a bill to form a “therapeutic psilocybin working group”, an endeavor that is sure to revolutionize medicinal practices and bring about ground-breaking breakthroughs in healthcare.
Psychedelic Decriminalization Update : Colorado, Oklahoma & Maine Move To Legalize Psychedelics?
Psychedelic Decriminalization Update Today, we take a look at 3…